Prostate cancer tumor biology can differ significantly based on whether a patient is Black or white, according to data from a ...

A large Department of Veterans Affairs cohort study revealed key racial differences in genomic alterations among men with metastatic prostate cancer.

Two cutting-edge research projects at Bar-Ilan University have been awarded Proof of Concept (PoC) Grants from the European Research Council (ERC)—a major achievement that highlights the university’s ...

An expert discusses how the PEACE III combination of radium-223 and enzalutamide represents an effective treatment option for the limited population of patients who reach first-line metastatic ...

Data from clinical trials have indicated that PSA is prognostic for outcomes, but little is known about real-world trends.

Effective from 1 October 2025, CMS and commercial health insurers will recognise the HCPCS Level II code A9616 assigned for reimbursement of Gozellix. The assignment of the code is a significant ...

A new study from University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why about one-third of prostate cancers respond especially poorly to treatment.

Scientists at the University of Michigan Rogel Cancer Center have found an important clue to why some men with advanced ...

A new study by University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why about ...

A new study from University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why ...

STAMPEDE otherwise follows a line of randomized trials (e.g., MAST, TAXOMET, IMPROVE) that have failed to prove cancer ...